Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Abstract Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to rem...
Main Authors: | Rodrigo Alonso-Navarro, Margarita Ramírez, Mar Masiá, Roger Paredes, Rocío Montejano, Marina Povar-Echeverria, Jordi Carratalà, Miguel Salavert, Enrique Bernal, Carlos Dueñas, Juan Flores, Francisco Fanjul, Isabel Gutiérrez, Verónica Rico, Lourdes Mateu, Julen Cadiñanos, Juan Berenguer, Alex Soriano |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12879-023-08222-y |
Similar Items
-
Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences — the Italian Military Hospital experience
by: Antonio Sabba, et al.
Published: (2023-09-01) -
The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
by: Mehran Amirizadeh, et al.
Published: (2023-11-01) -
The use of Remdesivir in pregnant women with COVID-19
by: Gulbanu Shaimerdenova, et al.
Published: (2023-02-01) -
Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven
by: Richard D. Shih, et al.
Published: (2020-12-01) -
Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
by: Flor álvarez de Toledo
Published: (2020-10-01)